Form DEFA14A Esperion Therapeutics,
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
| Filed by the Registrant ☒ | |||||||||||||||||
| Filed by a Party other than the Registrant ☐ | |||||||||||||||||
| Check the appropriate box: | |||||||||||||||||
| ☐ | Preliminary Proxy Statement | ||||||||||||||||
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||||||||||||||
| ☐ | Definitive Proxy Statement | ||||||||||||||||
| ☒ | Definitive Additional Materials | ||||||||||||||||
| ☐ | Soliciting Material under §240.14a-12 | ||||||||||||||||
| ESPERION THERAPEUTICS, INC. | ||||||||||||||
| (Name of Registrant as Specified In Its Charter) | ||||||||||||||
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) | ||||||||||||||
| Payment of Filing Fee (Check all boxes that apply): | ||||||||||||||
| ☒ | No fee required. | |||||||||||||
| ☐ | Fee paid previously with preliminary materials. | |||||||||||||
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 | |||||||||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blue Bell Private Wealth Management Welcomes Sean Miller as Investment Advisor Representative
- Tesla Second Quarter 2026 Production, Deliveries & Deployments
- The LGL Group, Inc. Announces Contract Award for Portfolio Company Precise Time and Frequency to Support Resilient Defense Communications in the Indo-Pacific Region
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
